Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial
Ana Oaknin(Hebron University), Paul DiSilvestro(Women & Infants Hospital of Rhode Island), Charlie Gourley(Edinburgh Cancer Research), Michael Friedländer(Prince of Wales Hospital), Alexandra Léary(Institut Gustave Roussy), Giovanni Scambia(Agostino Gemelli University Polyclinic), William H. Bradley(Froedtert Hospital), Gabe S. Sonke(Oncode Institute), Carol Aghajanian(Memorial Sloan Kettering Cancer Center), Susana Banerjee(Royal Marsden NHS Foundation Trust), Kathleen N. Moore(University of Oklahoma Medical Center), Amit M. Oza(Ontario Institute for Cancer Research), Ralph Bloomfield(AstraZeneca (United Kingdom)), Anne Floquet(Institut Bergonié), Nicoletta Colombo(University of Milano-Bicocca), E.S. Lowe(AstraZeneca (United States)), Alla Lisyanskaya(City Clinical Oncology Center), B.-G. Kim(Samsung Medical Center), Antonio González-Martı́n(Spanish Ovarian Cancer Research Group)
Cited by 14
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k